Ro-statin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ro-statin

Property Description
Active Ingredient Rosuvastatin Calcium
Form Oral Tablet
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
General Purpose Lipid-lowering and cardiovascular risk reduction
Origin Synthetic

What Kind of Medicine is Ro-statin?

Ro-statin is a prescription-only medication that falls within the class of drugs known as antilipemic agents, widely recognized as statins. Its active pharmaceutical ingredient is Rosuvastatin Calcium, which acts specifically as an HMG-CoA Reductase Inhibitor. Ro-statin itself represents a trade-named formulation of the compound, distinguished from generic versions primarily through manufacturing standards and specific formulation excipients.

The core substance, Rosuvastatin, is a synthetic compound whose classification as an HMG-CoA Reductase Inhibitor means it is designed to intervene directly in the initial, rate-limiting step of cholesterol production within the liver, a verified function of this drug class. This substance is clinically recognized for its high efficacy compared to other agents in this class, supporting its role as an established tool for managing high blood fat levels.

Composition, Form, and General Purpose

Ro-statin is provided as a single-ingredient product, typically formulated into an oral tablet for oral administration. The tablet contains the active substance, Rosuvastatin Calcium, combined with necessary solid pharmaceutical excipients.

The general purpose of Ro-statin is to function as a potent lipid-lowering agent. By reducing the concentration of fats in the bloodstream, particularly low-density lipoprotein cholesterol (LDL-C), the medication supports the overarching objective of cardiovascular risk reduction in patients with elevated blood lipids. Rosuvastatin is distinguished by its hydrophilic nature, which contributes to its selective uptake by the liver, its primary site of action.

Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information
  2. Rosuvastatin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Ro-statin?

Possible side effects and safety information for Ro-statin

The safety profile of Ro-statin (Rosuvastatin) is officially structured by government regulatory agencies, which classify documented adverse reactions by frequency and the body system affected.

Official Adverse Reaction Categories

Adverse effects are broadly grouped into classifications such as Common, Uncommon, and Rare events, encompassing disorders related to the Musculoskeletal, Hepatobiliary, Nervous System, and Gastrointestinal systems.

Adverse Event Classification System-Organ Class Examples
Common Nervous, Musculoskeletal Headache, Myalgia, Asthenia
Common Gastrointestinal Abdominal pain, Nausea, Constipation
Rare Musculoskeletal Rhabdomyolysis, Immune-Mediated Necrotizing Myopathy (IMNM)
Rare/Very Rare Hepatobiliary Hepatic failure (fatal and non-fatal)

Serious Reactions and Safety Constraints

The regulatory labels explicitly document rare but clinically significant events classified as Serious Adverse Reactions, including Rhabdomyolysis (severe muscle breakdown) and Hepatic failure. High-level safety constraints note that use is contraindicated in individuals with active liver disease (including unexplained persistent elevations of liver enzymes) and during pregnancy or lactation.

Safety data also note that certain renal effects, such as Proteinuria and Hematuria, are typically observed early in treatment or during changes in dosage. For specific populations, such as Asian patients, increased systemic exposure has been documented. This structured safety information defines the limits and potential risks associated with the medicine's official use.

Overdose and Emergency Response

Overdose and When to Seek Help

The Ro-statin regulatory profile states that the effects of an overdose are not explicitly described in detail. However, the management approach is based on the potential for severe, dose-dependent adverse reactions known to occur with statin toxicity.

Overdose Risk and Manifestations

The primary serious health risk addressed in the event of an overdose is rhabdomyolysis, a severe muscle injury that can lead to secondary acute renal failure (kidney damage). Monitoring is required for key indicators such as creatine kinase (CK) levels and general liver and kidney function.

Required Emergency Actions

Official prescribing information mandates that patients and caregivers seek immediate medical help or contact a Poison Control Center right away if an overdose is suspected. The medication should be discontinued.

Management Requirement Official Regulatory Statement
Antidote Status No specific treatment or antidote is available.
Treatment Focus Treatment must be symptomatic and supportive measures instituted as required.
Clearance Hemodialysis does not significantly enhance clearance of Ro-statin due to its high protein binding.

This strictly defined emergency protocol structures the entire overdose profile around risk mitigation and supportive care rather than a specific reversal agent.

Therapeutic Uses of Ro-statin

What Ro-statin Treats: Main Uses and Benefits

Ro-statin is relevant in contexts marked by increased discomfort or tension, particularly for conditions involving systemic imbalance related to lipids. The medication is applied across domains where additional symptomatic support is needed. It is commonly used across conditions presenting with disruptive symptom manifestations.


Supporting Systemic Lipid Management

Ro-statin helps address symptoms related to systemic imbalance and provides support that helps ease the overall burden of symptoms. This contributes to improved comfort during periods of heightened symptoms. It is often used when symptoms intensify and supportive relief is needed.


Assisting with Long-Term Functional Stability

This medication is considered relevant in contexts involving heightened systemic burden to help manage cardiovascular risk factors. It is applied when appropriate for conditions where functional stability becomes affected. Ro-statin may assist with maintaining functional stability and supports general well-being during symptomatic phases, making it useful in scenarios where symptoms escalate temporarily.


Quick Fact: Applied in contexts where additional support for symptom management is needed.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ro-statin — Official Regulatory Information


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults are approved for general use. Children/Adolescents (typically ge 6 years old) are approved for specific familial hypercholesterolemia conditions.
Populations for whom use is contraindicated Patients with active liver disease, pregnancy, or lactation (breastfeeding) are strictly prohibited from use.
Age-related eligibility rules Safety and efficacy are not established for children younger than 6 years of age. A lower 5 mg starting dose is advised for patients over 70 years of age.
Condition-specific eligibility rules The 40 mg maximum dose is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min), predisposing factors for myopathy (e.g., untreated hypothyroidism), or those receiving certain concomitant medications (e.g., Cyclosporine).
Eligibility-related restrictions Patients of Asian descent are generally advised a 5 mg starting dose due to known increases in rosuvastatin plasma concentrations.

Eligibility Classifications (High-Level)

Classification Severity and Context
Contraindicated Absolute exclusion based on physiological state (Pregnancy, Lactation) and organ function (Active Liver Disease).
Conditional Use Required lower starting dose or maximum dose restriction based on genetic factors (Asian Descent) and organ function (Severe Renal Impairment).

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Ro-statin based on strict absolute contraindications—such as active liver disease and pregnancy—which mandate exclusion. Beyond these, eligibility is governed by conditional restrictions related to age, race, and organ function, such as limiting the maximum dose for individuals with severe renal impairment or those of Asian descent. This structure ensures that use is only permitted within specific patient profiles documented as safe and effective by governmental authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ro-statin based on specific medicinal products and substance categories that may alter its concentration in the body or increase the risk of certain adverse events.

Key Interacting Agents and Constraints

Interacting Product Category Regulatory Constraint or Requirement
Cyclosporine (Immunosuppressant) Ro-statin dose must not exceed 5 mg once daily.
Gemfibrozil (Fibrate) Concomitant use should generally be avoided. If used, Ro-statin dose must not exceed 10 mg once daily.
Oral Anticoagulants (e.g., Warfarin) Requires appropriate monitoring of the patient's INR (International Normalized Ratio) upon initiation, dose change, or discontinuation of Ro-statin.
Aluminum/Magnesium Hydroxide Antacids Ro-statin must be administered at least 2 hours after the antacid.
Protease Inhibitors & Others (e.g., Simeprevir, Darolutamide) Specific maximum dose limits (e.g., 5 mg or 10 mg daily) are mandated due to increased exposure to Ro-statin.

These interactions are primarily driven by the co-administered agents affecting Ro-statin's metabolism or transport, such as inhibiting the OATP1B1 and BCRP transporters. Combinations with fibrates and colchicine are noted to increase the risk of myopathy, necessitating careful evaluation and adherence to dose restrictions specified in the official labeling.

Mechanism of Action

How Ro-statin Works: Mechanism of Action

Targeting the Core Cholesterol Synthesis Pathway

Ro-statin's primary action involves the highly selective and competitive inhibition of the liver enzyme HMG-CoA Reductase within hepatocytes. This enzyme is the rate-limiting control point for the mevalonate pathway, the fundamental process for the synthesis of cholesterol. This molecular blockade creates a significant intracellular shortage of cholesterol, triggering the subsequent phase of the drug's mechanism.


Enhancing Systemic Lipoprotein Clearance

In response to cholesterol deficiency, a robust feedback mechanism in liver cells is activated, causing a significant upregulation of LDL Receptors on the cell surface. This increased receptor density facilitates the liver's ability to extract Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream, resulting in a reduction in the concentration of circulating atherogenic lipoproteins.


Modulating Vascular and Inflammatory Systems

Beyond its key effect on lipids, the drug also modulates non-lipids through the reduction of isoprenoid intermediates. This pleiotropic effect involves the modulation of the vascular lining (endothelium) and a reduction in systemic biomarkers of inflammation.

Dosage and Administration Information

How to Use Ro-statin: Administration Guidelines

Ro-statin (Rosuvastatin Calcium) is administered orally as a single dose once daily (QD), and this routine constitutes a long-term treatment plan. The medication's usage is flexible concerning meals; it may be taken with or without food and at any time of day. The tablet should be swallowed whole and not crushed or split.


Standard Dosing and Administration Conditions

Treatment is initiated as an adjunct to a cholesterol-lowering diet, which must continue during therapy. Dosing is individualized, and adherence to labeled instructions is required to maintain the proper use profile:

  • Adult Dosing: The common starting dose is 10 mg or 20 mg once daily, with the maximum dose being 40 mg daily. Dose adjustments, if necessary, should only be made at intervals of four weeks or longer to allow time for the therapeutic response to be assessed.
  • Specific Populations: A lower starting dose of 5 mg once daily is recommended for patients of Asian descent and those with severe, non-dialysis-dependent renal impairment. For the latter group, the daily dose must not exceed 10 mg.
  • Missed Dose: If a daily dose is missed, patients are instructed to skip the missed dose and resume treatment with the next scheduled dose; taking an extra dose to compensate is not permitted.

Administration Constraints

For patients taking antacids containing aluminum and magnesium hydroxide, Ro-statin must be administered at least two hours before the antacid to avoid reduced absorption of the medicine. These usage constraints define the procedural framework for the safe and appropriate use of the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ro-statin

Evidence for Reducing Risk of First Cardiovascular Events

This section summarizes large-scale randomized controlled trials (RCTs) that was studied for use in seemingly healthy adults with specific risk factors but no prior history of heart disease. These studies explored whether managing these risk factors was associated with a difference in future cardiovascular outcomes. Researchers tracked a combined outcome that included serious events like nonfatal heart attack, nonfatal stroke, and cardiovascular death.

The large-scale trials reported patterns observed in the studies where a lower occurrence of these major adverse cardiovascular events was measured in the group receiving the study medicine compared to the group receiving a placebo over the trial duration. This evidence contributes to the broader evidence landscape where the medication was studied for use in individuals with specific cardiovascular risk profiles.

Evidence for Managing Blood Lipid Levels (Cholesterol and Triglycerides)

The effects of the active ingredient, Rosuvastatin, were evaluated in numerous short-term and intermediate-term randomized controlled trials against both a placebo and other similar medicines. These studies primarily examined outcomes related to systemic or functional imbalance by monitoring how lipid levels changed, including LDL-C, Total Cholesterol, and triglycerides (TG).

Studies reported consistent measurements of reduction in LDL-C and Total Cholesterol across diverse populations with elevated blood lipids. These findings describe patterns observed in the studies that were often dose-related, meaning higher studied amounts resulted in different measurements in the biomarkers. However, many of these comparative studies had follow-up durations that were limited, and comparative evidence is lacking for many direct, long-term comparisons against all competing statins concerning hard clinical outcomes.

Evidence for Use in Specific High-Risk Genetic Conditions

Research was studied for use in both adults and in pediatric and adolescent cohorts (typically starting from age six) diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH). Trials in children and adolescents reported findings describing measured differences in LDL-C levels during the study period. Additionally, longer observational studies monitored intermediate outcomes, such as the change in the thickness of the carotid artery walls (cIMT), an imaging marker of vascular health.

Since cardiovascular events take many decades to develop in these younger patients, there is limited information for long-term outcomes regarding the actual prevention of heart attack or stroke in these specific groups. Subgroup findings are uncertain, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Ro-statin (FAQ)


Q: Can taking Ro-statin affect my liver function?

A: According to official product information, increases in liver enzymes (serum transaminases) have been reported, which is often a sign of how the liver processes the medicine. There are also rare reports of fatal and non-fatal hepatic (liver) failure. For this reason, official safety constraints note that liver enzyme testing is commonly performed or considered before and during therapy.


Q: Are there any known interactions between Ro-statin and grapefruit?

A: The active ingredient in Ro-statin is less likely to interact with grapefruit compared to certain other statins, according to official information. This is because the drug's metabolism is not significantly affected by the specific liver enzyme that grapefruit typically interferes with.


Q: What kind of monitoring (like blood tests) is needed while taking Ro-statin?

A: The product label specifies that liver enzyme testing is recommended before starting treatment and as clinically indicated thereafter. Testing of Creatine Kinase (CK) levels, which is a marker for muscle breakdown, is part of the clinical assessment for unexplained muscle symptoms.


Q: What should I do if the muscle aches from Ro-statin become severe?

A: Official regulatory safety information indicates that unexplained muscle pain, tenderness, or weakness should be reported to a healthcare provider for evaluation. This is particularly important if the symptoms are accompanied by malaise (a general feeling of discomfort) or fever, as these may be signs of a rare but serious muscle condition.


Q: Is it normal to feel a bit nauseous when first starting Ro-statin?

A: Regulatory documents classify nausea as a common side effect, meaning it has been frequently reported (in 1% to 10% of patients) in clinical studies. Given the classification as a common side effect, nausea is a frequently reported experience when beginning the medication.


Q: Is Ro-statin the same as other statin medications like Lipitor or Crestor?

A: Ro-statin is the trade name for the active ingredient Rosuvastatin Calcium, which is one specific type of statin medication. Crestor is also a brand name for rosuvastatin. Lipitor, however, contains a different statin drug called atorvastatin. While all belong to the statin drug class, they are distinct medications with different active ingredients and trade names.


Q: What are the most common side effects people report when starting Ro-statin?

A: According to official regulatory summaries of clinical trial data, the most frequent adverse reactions reported (rate ge 2%) include headache, myalgia (muscle pain), abdominal pain, asthenia (weakness or lack of energy), and nausea.


Q: Is it safe to drink alcohol while taking Ro-statin?

A: Official labeling includes a warning related to patients with a history of alcohol abuse or liver disease. Drinking large amounts of alcohol while using rosuvastatin could potentially increase the risk of liver-related side effects. The decision regarding alcohol consumption should be made in consultation with a healthcare professional.


Q: How long do most people need to stay on Ro-statin?

A: The medication is approved for use as an addition to diet for the reduction of high blood fats, which is a condition that often requires long-term, ongoing therapy to manage risk. Any decision regarding the duration or stopping of treatment should be determined by a healthcare professional.


Q: Does Ro-statin have any long-term side effects that are concerning?

A: Serious rare events such as fatal and non-fatal hepatic failure and rhabdomyolysis are officially noted. Postmarketing reports also mention rare instances of cognitive impairment (like memory loss/confusion) and peripheral neuropathy (nerve damage). These effects are generally reported to be reversible upon discontinuation.


Q: Is Ro-statin safe for older adults or seniors?

A: Ro-statin is indicated for use in adult populations, including seniors. The official label specifies that for patients 70 years of age and older, a lower starting dose (5 mg) is advised due to potential increased exposure and risk of muscle-related issues.


Q: Does Ro-statin help with high blood pressure, or just cholesterol?

A: The official approved indications for Ro-statin focus on reducing elevated cholesterol, triglycerides, and overall cardiovascular risk. It is not approved or indicated by regulatory agencies as a specific treatment for high blood pressure.


Q: Can Ro-statin cause memory problems or confusion?

A: Yes, there have been rare reports from postmarketing surveillance of cognitive impairment (such as memory loss, forgetfulness, and confusion) associated with statin use. Regulatory documents note that these effects are typically not serious and usually reverse once the medication is stopped.


Q: Is Ro-statin suitable for people with diabetes?

A: Official safety data has noted that statins, including Ro-statin, can cause small increases in HbA1 c and fasting blood sugar levels. The decision to use Ro-statin in patients with diabetes involves a clinical assessment of individual cardiovascular risk factors.


Q: Is there a generic version of Ro-statin available?

A: Yes, the active ingredient in Ro-statin, Rosuvastatin Calcium, has approved generic versions available from various manufacturers. These generic versions contain the same active ingredient and meet the same regulatory standards for quality and effectiveness.


Q: Does Ro-statin cause weight gain or loss?

A: Official regulatory documents do not list weight gain or loss among the common or frequent side effects reported in clinical trials. Studies involving specific patient populations, such as children, showed no detectable effect on weight or Body Mass Index (BMI) during the trial period.


Q: Is Ro-statin safe for teenagers or children?

A: Ro-statin is approved for specific uses in children and adolescents. It is indicated for patients aged 8 years and older with Heterozygous Familial Hypercholesterolemia (HeFH) and aged 7 years and older with Homozygous Familial Hypercholesterolemia (HoFH). Safety has not been established for children under 6 years of age.


Q: Can I stop taking Ro-statin once my cholesterol is at a healthy level?

A: The medication is intended as a long-term treatment to help reduce the risk of cardiovascular events. Stopping the medication may cause lipid levels to rise again. The long-term nature of this therapy means that any decision to stop the medication must be discussed with and guided by a healthcare professional.


Q: Why is Ro-statin considered a 'statin' drug?

A: Ro-statin is classified as a statin because its active ingredient, Rosuvastatin, belongs to the class of drugs known as HMG-CoA Reductase Inhibitors. It works by selectively inhibiting the HMG-CoA reductase enzyme in the liver.


Q: Do lifestyle changes still matter when taking Ro-statin?

A: Yes, official regulatory documents indicate that Ro-statin is intended for use as an adjunct to diet and other non-pharmacologic measures. Maintaining a cholesterol-lowering diet, exercising, and managing weight are all officially considered important parts of the overall treatment plan.


Q: Is it possible to be allergic to the ingredients in Ro-statin?

A: Yes, the medication is contraindicated for patients with known hypersensitivity (an allergic reaction) to the active ingredient, Rosuvastatin, or to any of the other components (excipients) in the tablet.


Q: What are the main benefits of Ro-statin besides lowering cholesterol?

A: The main benefit, beyond the mechanism of lowering cholesterol, is the reduction of major cardiovascular events. This includes lowering the risk of nonfatal heart attack, nonfatal stroke, and cardiovascular death in high-risk patients. It is also indicated to help slow the progression of atherosclerosis (arterial plaque buildup).


Q: Can Ro-statin cause problems with tendons or joints?

A: In clinical trials, joint pain (arthralgia) was reported. Official postmarketing reports also include cases of tendon disorders, which have sometimes been complicated by tendon rupture. These are generally considered rare events.


Q: Can Ro-statin make you feel unusually tired or fatigued?

A: Yes, official product information lists asthenia (a physical lack of energy, weakness, or feeling tired) as one of the most frequent adverse reactions reported in studies, occurring in 2% or more of patients.


Q: Does Ro-statin help reduce inflammation in the body?

A: Ro-statin is indicated to reduce the risk of major cardiovascular events in adults who have elevated risk factors, including an elevated high-sensitivity C-reactive protein (hsCRP). This is a biomarker used by doctors to assess systemic inflammation, indicating that the medication is studied and used in the context of reducing cardiovascular risk associated with elevated systemic inflammation.


Q: Why do some people experience stomach issues like gas or diarrhea on Ro-statin?

A: The regulatory documents list several common gastrointestinal side effects reported in clinical trials, including abdominal pain, nausea, and constipation. Diarrhea has also been reported in postmarketing surveillance. These symptoms are generally mild and may decrease over time.


Q: Is it normal for my urine to look darker when taking Ro-statin?

A: Dark urine is not listed as a common side effect of the medication. However, official safety guidance specifies that symptoms like dark urine should be promptly reported to a healthcare provider. Dark urine can be a sign of rhabdomyolysis, a rare but serious muscle condition that can affect the kidneys.


Q: Can Ro-statin cause nerve damage or tingling sensations?

A: Yes, official postmarketing reports include rare cases of Peripheral Neuropathy, which is damage to the nerves outside of the brain and spinal cord. Symptoms of this condition can include tingling, numbness, or weakness in the extremities.


Q: How is the effectiveness of Ro-statin measured by a doctor?

A: Effectiveness is clinically measured primarily by monitoring the reduction of elevated lipid levels in the bloodstream. This includes tracking the lowering of 'bad' cholesterol, specifically Low-Density Lipoprotein Cholesterol (LDL-C). Over the long term, effectiveness is judged by the reduction in the risk of major cardiovascular events.


Q: Is Ro-statin suitable for people with specific genetic conditions related to cholesterol?

A: Yes, Ro-statin is specifically indicated in both adult and pediatric patients with certain genetic conditions that cause very high cholesterol. This includes Heterozygous Familial Hypercholesterolemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH).


Q: What are the most serious, but rare, side effects of Ro-statin?

A: According to official regulatory warnings and precautions, the most serious but rare side effects include Rhabdomyolysis (severe muscle breakdown), Hepatic Failure (liver failure), and Immune-Mediated Necrotizing Myopathy (IMNM). These conditions are classified as serious adverse reactions that require prompt medical evaluation.


Q: What are the ingredients in Ro-statin tablets?

A: The active ingredient in Ro-statin is Rosuvastatin Calcium. The tablets also contain several inactive ingredients, or excipients, which are necessary for the pill formulation. The full list of ingredients can be found in the description or prescribing information on the official product label.

How should Ro-statin be stored and disposed of?

How to Store and Dispose of Ro-statin: Official Requirements

Storage and disposal instructions for Ro-statin (Rosuvastatin) are defined by government regulatory agencies to maintain the medicine’s integrity and safety.

Labeled Storage Conditions

Requirement Official Instruction
Temperature Store at a controlled room temperature, typically between 15 C and 30 C or below 25 C.
Protection Protect from excess moisture and light. Store away from heat and do not freeze.
Packaging Keep the medicine in its original, tightly closed container or blister packaging to maintain stability.

Official Disposal and Safety Rules

Regulatory documents mandate that the medicine be stored out of the reach of children and that child-resistant caps be used. When disposing of unused or expired Ro-statin, follow local official guidelines, such as drug take-back programs. The medicine should not be disposed of by flushing it down a toilet or pouring it down a drain unless specifically instructed by a government authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ro-statin found in:

A-Z Index: